Tranexamic Acid
Osteoarthritis, Hip
Floatz Rating
BB65/100
Confidence
Indicative
Sponsor
Konkuk University Medical Center
Modality
Small molecule
Development Phase
Phase 4 / Approved
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
50Indicative
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT05957822CT.gov Goal-directed vs Preemptive Tranexamic Acid Administration in Non-cardiac Surgery | — | Unknown | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Osteoarthritis, Hip
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Tranexamic Acid (this asset) | Konkuk University Medical Center | Approved | BB · 65 |
| Ropivacaine | Poznan University of Medical Sciences | P4 | BBB |
| Dexasone | Poznan University of Medical Sciences | P4 | BBB |
| Celecoxib | Pfizer | P4 | BB |
| Intravenous Dexamethsone | Poznan University of Medical Sciences | P4 | BB |
| Remimazolam | Seoul National University Hospital | P4 | BB |
| Oxycodone | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | P3 | BB |
| Dexmedetomidine | Poznan University of Medical Sciences | P4 | BB |
| cov155 | Mallinckrodt | P3 | BB |
+7 more in the Osteoarthritis, Hip cohort
Other indications for Tranexamic Acid
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Intracerebral Hemorrhage | — | P4 | BB · 71 |
| Post-Operative Wound Seroma, Non-Human Animal | — | P4 | BB · 69 |
| Brain Injury | — | P3 | BB · 68 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Citation
Floatz Terminal. Tranexamic Acid in Osteoarthritis, Hip. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 13, 2026. https://terminal.floatz.ai/assets/tranexamic-acid-osteoarthritis-hip
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →